An observational study in Sleep Apnea, Obstructive, sponsored by Groupe Adène. Recruiting at 1 site in France. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Groupe Adène · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 52nd largest by planned enrollment of the 67 observational ones that give a count, is one of 13 that started in 2025, is one of 67 observational ones, reaches primary completion later than 29 of the 47 other live ones, and was the 181st registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–75
Hospices Civils de Lyon · Sites in France
Ages 4–17
University Hospital, Grenoble · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–84
Hospices Civils de Lyon · Sites in France
Ages 5 mo–6 mo
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 3 Years to 7 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 52 across the 133 interventional studies, 140 across the 67 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 201 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Groupe Adène as lead sponsor.
Groupe Adène has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
13 of the studies in Sleep Apnea, Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05939934University Hospital, AngersImpact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal | 2026-11 |
| NCT07792746Clinique du MillenaireSleep Apnea Biomarkers and Adherence to Continuous Positive Airway Pressure | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if changes in quality of life are linked to changes in mouth opening after adenotonsillectomy in a group of children who were diagnosed with Type 1 Obstructive Sleep Apnea (OSA1). The main questions it aims to answer are:
Primary Objective:
•Are changes in quality of life linked to improvements in mouth opening after adenotonsillectomy?
Secondary Objectives:
Participation will require:
STUDY BACKGROUND AND OBJECTIVES Obstructive Sleep Disordered Breathing (oSDB) encompasses a range of abnormal breathing patterns during sleep, from snoring to complete airway obstruction, caused by increased upper airway resistance and pharyngeal collapsibility. Although often considered an adult disease, oSDB also occurs in children, and has been linked to metabolic, cardiovascular, and neurocognitive morbidity, and lower quality of life in pediatric patients. This study focuses on children who have Type 1 Obstructive Sleep Apnea (OSA1), a condition where a person's airway can become blocked repeatedly during sleep. The common treatment for OSA1 is adenotonsillectomy.
OSA1 is diagnosed and evaluated using the Apnea-Hypopnea Index (AHI), which is considered an indicator of OSA severity. Polysomnography (PSG), the gold standard for measuring AHI, is a time consuming and costly procedure that is impractical for follow-up in a pediatric population. Furthermore, AHI has not been shown to be related to quality of life in children with OSA1. For this reason, interest in using measuring mouth opening, instead of PSG, to evaluate OSA1 has grown. Mouth opening reflects mouth breathing, a common clinical feature of OSA1 that is linked to respiratory effort. In children with OSA1, improvements in mouth breathing have been associated with better behavior, decreased sleepiness, and increased quality of life.
The Jawac© is a novel technology that can be used to reliably measure jaw activity, which is used to evaluate mouth opening, in children. Previous research has shown that changes in respiratory effort-related arousal after adenotonsillectomy were related to changes in mandibular movement. However, no previous research has identified a straightforward, objective biomarker that correlates with quality of life and surgical outcomes in children undergoing adenotonsillectomy. Given the observed links between mouth opening, respiratory effort, and quality of life in pediatric patients, the primary objective of this clinical trial is to determine if changes in quality of life are linked to changes in mouth opening after adenotonsillectomy in a group of children who were diagnosed with OSA1. The secondary aims include studying the relationships between change in quality of life and changes in common Jawac and PSG metrics as well as evaluating variations in quality of life, changes in clinical symptoms, and the relationship between Jawac and PSG metrics in the same population of children who undergo adenotonsillectomy.
STUDY DESIGN AND METHODS This research study is non-randomized, monocentric, prospective, and features a single non-blinded arm due to its exploratory and descriptive nature. During the pre-inclusion visit (V0), surgeons will screen patients for eligibility to participate in the study. At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements. The adenotonsillectomy will occur during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires. Four months post-surgery, patients will have a follow-up consultation with the surgeon (V4). The study protocol adheres to national guidelines for standard OSA management, with the addition of the questionnaires at V1 and V3, and the PSG with Jaw activity (measured using the Jawac) measurement at V3. Only one extra consultation (V3) is added to the standard patient pathway, thus a low rate of study discontinuation is anticipated. Data from patients who discontinue or deviate from the intervention will be excluded. Adverse events will be documented throughout the study at V1, V2, V3, and V4.
The study population will include pediatric patients between the ages of three and seven years old, who consulted with a surgeon at the study center for potential adenotonsillectomy. To be eligible to participate, patients must be beneficiaries of the French single payer national medical insurance system, be able to attend all scheduled visits and comply with trial procedures, and legal guardians must give informed consent. Full inclusion and exclusion criteria are listed in Table 1. The study center is a private French hospital that, due to the single-payer insurance system in France, should include patients from a range of socioeconomic categories and geographical (urban versus rural) locations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is a non-randomized, monocentric, prospective trial with a non-blinded single arm. All participants need to have received a surgical indication for adenotonsillectomy to be included in the study. The participants will undergo polysomnography coupled with measurements of mouth opening (using the Jawac) before and after the adenotonsillectomy. Each participant's parent or legal guardian will also complete questionnaires that will provide information about the participant's quality of life and symptoms.
Device: Measures of jaw activity using the Jawac
At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements of jaw activity. Patients will undergo adenotonsillectomy during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires.
Correlation between change in quality of life and change in mouth opening
Quality of life (QOL) will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. The JAWAC sensor will be used to measure Mouth Opening in 1/10 millimeters to assess oral breathing during sleep. Oral breathing is a potential cause of sleep apnea in children. Higher measures of Mouth Opening (in millimeters) indicates a greater degree of respiratory disturbance during sleep. The main endpoint analysis (correlation between change in QOL and change in Mouth Opening) will be done using the estimation of the ρ coefficient. A linear regression will be used for the analysis before and after adjustment for confounding variables.
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).
Changes in quality of life
QOL will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. The same parent or legal guardian will complete the PedsQL at inclusion (V1) and three months after adenotonsillectomy (V3)
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).
The correlations between changes in quality of life and changes in other mandibular movement metrics
Quality of life (QOL) will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. The mandibular movement (MM) measures that will be evaluated using the Jawac are: large MM (MML): the number of MM amplitudes ≥0.3 mm from peak to peak during ≥two respiratory cycles; Sharp MM (MMS): the number of sudden large MMs (amplitude \>1mm and/or amplitude ≥200% of the previous and/or the ensuing MM amplitude) during one respiratory cycle; Mandibular movement opening (MMO): how wide the mouth opens (in mm) during MM; Time durations during non-rapid eye movement sleep when mandibular movement is higher than 0.4 mm (tMM0.4), 0.3 mm (tMM0.3), and 0.2 mm (tMM0.2). Correlation analyses will be conducted
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).
The relationship between changes in quality of life and changes in polysomnography respiratory disturbance index
Quality of life (QOL) will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. Polysomnography respiratory disturbance index (PSG-RDI), which measures the number of abnormal breathing events per hour of sleep, will be evaluated as defined by the American Academy of Sleep Medicine 2018. PSG-RDI defines sleep apnea severity as follows: normal: \<5 events/hr; mild: ≥5 but \<15 events/hr; moderate: ≥15 but \<30 events/hr; severe: ≥30 events/hr. A linear regression will be used for the analysis before and after adjustment for confounding variables
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).
Changes in the Sleep-related Breathing Disorder scale
Clinical symptoms will be evaluated using The Sleep-related Breathing Disorder scale of the Pediatric Sleep Questionnaire (PSQ), which consists of 22 items. The score is the mean response on non-missing items, which can vary from 0 to 1. Higher scores reflect high risk for a pediatric sleep-related breathing disorder.
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).
Correlations between mandibular movement and Polysomnography respiratory disturbance index
The mandibular movement (MM) measures that will be evaluated using the Jawac are: large MM (MML): the number of MM amplitudes ≥0.3 mm from peak to peak during ≥two respiratory cycles; Sharp MM (MMS): the number of sudden large MMs (amplitude \>1mm and/or amplitude ≥200% of the previous and/or the ensuing MM amplitude) during one respiratory cycle; Mandibular movement opening (MMO): how wide the mouth opens (in mm) during MM; Time durations during non-rapid eye movement sleep when mandibular movement is higher than 0.4 mm (tMM0.4), 0.3 mm (tMM0.3), and 0.2 mm (tMM0.2). Polysomnography respiratory disturbance index (PSG-RDI), which measures the number of abnormal breathing events per hour of sleep, will be evaluated as defined by the American Academy of Sleep Medicine 2018. PSG-RDI defines sleep apnea severity as follows: normal: \<5 events/hr; mild: ≥5 but \<15 events/hr; moderate: ≥15 but \<30 events/hr; severe: ≥30 events/hr. Correlation analyses will be conducted
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).
Changes in acute sleep disturbances
The Sleep Disturbance Scale for Children (SDSC) (separate versions for 3-4 and for 5-7 year olds) has 26 items, scored from 1-5 (maximmum score 130, minimum score 1). Higher scores indicate more acute sleep disturbances.
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3)
Changes in emotional and behavioral difficulties
The Strengths and Difficulties Questionnaire (SDQ) (separate versions for 3-4 and 5-7 year olds) has 25 items divided into 5 scales (score range: 0-40). Higher total scores suggest significant emotional and behavioral difficulties.
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3)
Severity Hierarchy Score for Respiratory Symptoms
The Severity Hierarchy Score (SHS) will be used to rank respiratory symptoms from least to most severe. It does not have defined maximum and minimum scores.
Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3)
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 22 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Oct 2025 → Dec 2025, primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.